Erypro 4000 Injection contains Recombinant Human Erythropoietin Alfa at a concentration of 4000 IU/ml, a glycoprotein hormone that stimulates erythropoiesis, the production of red blood cells, by acting on erythroid progenitor cells in the bone marrow. It is primarily indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not yet on dialysis, as well as anemia due to chemotherapy in cancer patients. Erypro 4000 Injection is also used to reduce the need for allogeneic blood transfusions in surgical patients and in other conditions where anemia is a significant clinical concern. The administration of Erypro 4000 should be individualized based on hemoglobin levels and clinical response, with careful monitoring to avoid excessive erythropoiesis, which may increase the risk of cardiovascular events. Common side effects include hypertension, headache, and injection site reactions. It is contraindicated in patients with uncontrolled hypertension and known hypersensitivity to erythropoietin or any component of the formulation. Dose adjustments are necessary in patients with iron deficiency, which should be corrected prior to and during therapy to ensure optimal response. Erypro 4000 Injection should be administered under medical supervision with appropriate laboratory monitoring.

Dosage & How to Use